SCHEMBL14715152

SCHEMBL14715152

CNC(=O)C(C(=O)OC)N(C)C(=O)c1ccc(-c2ccc(N(C)C(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ PAX8 Q06710 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14724512 0.86 PAX8 (0.40) PAX8
SCHEMBL14715165 0.81 — —
SCHEMBL14714746 0.80 — —
SCHEMBL14789212 0.78 — —
SCHEMBL14714535 0.78 — —
SCHEMBL14789211 0.78 ALDH1A1 (0.43) —
SCHEMBL14789086 0.78 — —
SCHEMBL14786636 0.78 CA12 (0.34) —
SCHEMBL21094150 0.77 TDP1 (0.42) —
SCHEMBL14789139 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 — — EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 — — US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 — — US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 — — US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 — — US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 — — US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 — — US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 — — US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 — — US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 — — US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 PAX8 3509/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 PAX8 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback